Clinical trial
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
NCT00428545 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00428545 |
|---|---|
| Title | Bevacizumab and Bortezomib in Patients With Advanced Malignancy |
| Official title | A Phase I Trial of Bevacizumab and Bortezomib in Patients With Advanced Malignancy |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Malignancy, Lymphoma, Myeloma, Solid Tumors |
| Intervention type | Drug |
| Interventions | Bevacizumab, Bortezomib |
| Enrollment | 104 |
| Start date | Jan 1, 2007 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Jan 30, 2007 |
| Last update posted | Feb 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: